Patents by Inventor Annemieke Aartsma-Rus

Annemieke Aartsma-Rus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR EFFICIENT EXON (44) SKIPPING IN DUCHENNE MUSCULAR DYSTROPHY AND ASSOCIATED MEANS
    Publication number: 20210207138
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO:1), 5?-GGGAACAUGCUAAAUAC (SEQ ID NO:2), 5?-AGACACAAAUUCCUGAGA (SEQ ID NO:3), or 5?-CUGUUGAGAAA (SEQ ID NO. 4), and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: December 11, 2020
    Publication date: July 8, 2021
    Inventors: Gerard Johannes Platenburg, Josephus Johannes De Kimpe, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus
  • ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS
    Publication number: 20200332298
    Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 22, 2020
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONS
    Publication number: 20200224203
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: February 4, 2020
    Publication date: July 16, 2020
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions
    Patent number: 10590421
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 17, 2020
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • METHOD FOR EFFICIENT EXON (44) SKIPPING IN DUCHENNE MUSCULAR DYSTROPHY AND ASSOCIATED MEANS
    Publication number: 20190292541
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Gerard Johannes Platenburg, Josephus Johannes De Kimpe, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus
  • Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
    Patent number: 10364432
    Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: July 30, 2019
    Assignee: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
    Patent number: 10246707
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 2, 2019
    Assignees: Biomarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Gerard Johannes Platenburg, Josephus Johannes de Kimpe, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen, Annemieke Aartsma-Rus
  • Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
    Patent number: 10113165
    Abstract: The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: October 30, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Judith Christina Theodora Van Deutekom, Garrit-Jan B. van Ommen, Annemieke Aartsma-Rus, Johannes Theodorus den Dunnen
  • Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
    Patent number: 9926557
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolated muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 27, 2018
    Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Josephus Johannes De Kimpe, Gerardus Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
    Patent number: 9896687
    Abstract: The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: February 20, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Garrit-Jan Boudewijn van Ommen, Judith Christina Theodora van Deutekom, Johannes Theodorus den Dunnen, Annemieke Aartsma-Rus
  • ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONS
    Publication number: 20170226521
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 10, 2017
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS
    Publication number: 20170175117
    Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 22, 2017
    Applicant: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
    Patent number: 9611471
    Abstract: Described are means and methods for removing a proteolytic cleavage site from a protein, the method comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, and allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: April 4, 2017
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS
    Publication number: 20160304864
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Application
    Filed: January 7, 2016
    Publication date: October 20, 2016
    Inventors: Josephus Johannes De KIMPE, Gerard Johannes PLATENBURG, Judith Christina Theodora Van DEUTEKOM, Annemieke AARTSMA-RUS, Garrit-Jan Boudewijn Van OMMEN
  • MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
    Publication number: 20160251658
    Abstract: The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides.
    Type: Application
    Filed: March 1, 2016
    Publication date: September 1, 2016
    Inventors: Judith Christina Theodora Van DEUTEKOM, Garrit-Jan Boudewijn Van OMMEN, Annemieke AARTSMA-RUS, Johannes Theodorus den DUNNEN
  • MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
    Publication number: 20160194636
    Abstract: The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides.
    Type: Application
    Filed: February 18, 2016
    Publication date: July 7, 2016
    Inventors: Judith Christina Theodora Van DEUTEKOM, Garrit-Jan Boudewijn Van OMMEN, Annemieke AARTSMA-RUS, Johannes Theodorus den DUNNEN
  • MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
    Publication number: 20160168570
    Abstract: The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 16, 2016
    Inventors: Judith Christina Theodora Van DEUTEKOM, Garrit-Jan Boudewijn Van OMMEN, Annemieke AARTSMA-RUS, Johannes Theodorus den DUNNEN
  • METHOD FOR EFFICIENT EXON (44) SKIPPING IN DUCHENNE MUSCULAR DYSTROPHY AND ASSOCIATED MEANS
    Publication number: 20160053262
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: September 21, 2015
    Publication date: February 25, 2016
    Inventors: Gerard Johannes Platenburg, Josephus Johannes de Kimpe, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen, Annemieke Aartsma-Rus
  • Means and methods for counteracting muscle disorders
    Patent number: 9243245
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: January 26, 2016
    Assignees: Academisch Ziekenhuis Leiden, BioMarin Technologies B.V.
    Inventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Means and methods for counteracting muscle disorders
    Patent number: RE48468
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 16, 2021
    Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen